Written question asked by Craig Tracey (Conservative) on Monday, 18 March 2024, in the House of Commons. It was due for an answer on Wednesday, 20 March 2024. It was answered by Andrew Stephenson (Conservative) on Thursday, 21 March 2024 on behalf of the Department of Health and Social Care.

Trastuzumab Deruxtecan

Question: To ask the Secretary of State for Health and Social Care, if she will make an assessment of the potential impact of the decision by the National Institute for Health and Care Excellence to not recommend trastuzumab deruxtecan for HER2-low secondary breast cancer for use on NHS on the life expectancy of eligible women.

Answer: The National Institute for Health and Care Excellence (NICE) has not yet published final guidance on the use of trastuzumab deruxtecan (Enhertu) for the treatment of metastatic HER2-low breast cancer. The NICE published final draft guidance on 5 March 2024, that does not recommend it as a clinically and cost-effective use of National Health Service resources. Stakeholders had until 19 March 2024 to lodge an appeal against the NICE’s recommendations. The NICE currently expects to publish final guidance on 3 April 2024.

Secondary information